Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00214734 · ClinicalTrials.gov registry record

ADVATE Post Authorization Safety Surveillance

A clinical trial of Hemophilia A, sponsored by Baxalta now part of Shire.

Completed
Registry status
108
Enrollment target
20
Study locations

NCT00214734: Completed study of Hemophilia A, sponsored by Baxalta now part of Shire.

NCT00214734 is a study of Hemophilia A that has completed, run by Baxalta now part of Shire. The registered enrollment target is 108 participants, above the 89-participant average among 42 other Hemophilia A trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00214734, a study of Hemophilia A, has completed, sponsored by Baxalta now part of Shire.

COMPLETED
Registry status
108 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this post-authorization safety surveillance is to measure the incidence of adverse events that are at least possibly related to ADVATE use, in subjects receiving ADVATE in routine clinical practice.

Conditions Studied

Interventions

  • DRUG rAHF-PFM

Study Locations (20)

Florida

  • Children'S Hospital of S.W. Florida - Fort Myers
  • BIODORON - Hollywood
  • Nemours Children'S Clinic - Jacksonville
  • NEMOURS CHILDREN'S CLINIC- Orlando - Orlando
  • Tampa Children'S Hospital At St. Joes - Tampa
  • University of Southern Florida - Tampa

California

  • City of Hope National Medical Center - Duarte
  • LONG BEACH MEMORIAL MED Center - Long Beach
  • Children´s Hospital Los Angeles, Hemophilia Comprehensive Care Center, Division of Pediatric Hematology/Oncology - Los Angeles
  • Valley Children'S Hospital - Madera

Illinois

  • Rush Presbyterian - St. Lukes Medical Center - Chicago
  • Children´s Memorial Hospital - Chicago

Michigan

  • University of Michigan Med. Ctr Htc - Ann Arbor
  • Henry Ford Hospital - Detroit

Arizona

  • PHOENIX CHILDRENS Hospital - Phoenix

Arkansas

  • Arkansas Childrens Hospital - Little Rock

Indiana

  • Indiana Hemophilia & Thrombosis Center - Indianapolis

Iowa

  • University of Iowa Hospitals and Clinics, Iowa Regional Hemophilia Center, Department of Pediatrics - Iowa City

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2004-10-14
Est. Completion 2007-03-02
Baxalta now part of Shire

74 total trials

What the finished NCT00214734 record still lists

NCT00214734 is an observational study that tracks outcomes without assigning an intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, above the 89-participant average among 42 other Hemophilia A trials with a reported enrollment target (21% higher).

The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which rAHF-PFM is the first listed.

NCT00214734 names 20 study sites across 10 states, led by Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT00214734 about?

NCT00214734 is a clinical study titled "ADVATE Post Authorization Safety Surveillance". The primary objective of this post-authorization safety surveillance is to measure the incidence of adverse events that are at least possibly related to ADVATE use, in subjects receiving ADVATE in routine clinical practice.

What is the current status of trial NCT00214734?

This trial is currently completed. The enrollment target is 108 participants. The study started on 2004-10-14. Estimated completion is 2007-03-02.

What conditions does trial NCT00214734 study?

This clinical trial studies the following conditions: Hemophilia A.

What interventions are being tested in trial NCT00214734?

The interventions under investigation include: rAHF-PFM (DRUG).

Who is sponsoring clinical trial NCT00214734?

This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00214734 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hemophilia A

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00214734's enrollment target sits among peer trials

108 12th of 42 higher than 31 of 42 other Hemophilia A trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02703207 · 108 participants · NA

    Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD

  • NCT02744677 · 108 participants · NA

    COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

  • NCT02781883 · 108 participants · Phase 2

    Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

  • NCT03848663 · 108 participants · NA

    Visual Remapping to Aid Reading With Field Loss

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00214734, the US trial registry maintained by the National Library of Medicine. NCT00214734 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.